Alpelisib Plus Fulvestrant in Patient... - SHARE Metastatic ...

SHARE Metastatic Breast Cancer

6,607 members8,142 posts

Alpelisib Plus Fulvestrant in Patients With HR+, HER2− Advanced Breast Cancer

Hazelgreen profile image
5 Replies

July 09, 2022

Alpelisib Plus Fulvestrant in Patients With HR+, HER2− Advanced Breast Cancer

Journal of Clinical Oncology ascopubs.org/doi/abs/10.120...

TAKE-HOME MESSAGE

This biomarker analysis of the SOLAR-1 trial showed that alpelisib plus fulvestrant had a clinical benefit regardless of the gene mutation status in patients with HR+, HER2− advanced breast cancer (ABC), including those with FGFR1 or FGFR2 alterations. A limited benefit of alpelisib was noted in patients with the MYC mutation compared with placebo.

The clinical benefit with alpelisib plus fulvestrant was maintained in this patient population, regardless of alterations in most biomarkers, including ESR1 and genes implicated in CDK4/6i resistance (eg, CCND1, MAP3K1, and FGFR).

– Jing Xi, MD, MPH

Written by
Hazelgreen profile image
Hazelgreen
To view profiles and participate in discussions please or .
Read more about...
5 Replies
GollyG profile image
GollyG

Thanks so much for sharing - the 'take home' is hugely appreciated. I'm waiting to see if I develop the mutation to get me on a trial for the oral SERD but as it's double blind, I think I will push for swapping in fulvestrant in place of letrozole instead.All the best,

Gill

Adele_Julia profile image
Adele_Julia

I have Piqray and Fulvestrant and so far they work magically together !

Hazelgreen profile image
Hazelgreen

For those who haven't googled, "Alpelisib":

"Alpelisib is a novel therapy approved for HR-positive, HER2-negative breast cancer in patients who have progressed on first-line hormonal therapies. Alpelisib's novel mechanism selectively inhibits the PI3K pathway, a driver mutation found in HR-positive, HER2-negative breast cancers."

"What kind of drug is alpelisib? Alpelisib is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells."

Mumberly profile image
Mumberly

Thank you for sharing your findings ♥️.

I don’t do a deep dive into the links, but I like the summary, and it provides hope that research is coming up with effective treatments for the future.

I hope you are doing well.

Kim

Bettybuckets profile image
Bettybuckets

Hi Miss Hazel, that was so helpful!

You may also like...

Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer

fulvestrant compared with fulvestrant alone in patients with HR+/HER2− advanced breast cancer...

Overall Survival With Palbociclib and Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer

palbociclib plus fulvestrant compared with fulvestrant alone in patients with HR+/HER2−...

Real-world study of overall survival with palbociclib plus aromatase inhibitor in HR+/HER2− metastatic breast cancer

2–negative (HR+/HER2−) metastatic breast cancer (MBC) treated with first-line palbociclib plus an...

Piqray/Alpelisib (plus Fulvestrant injections) Trial so far

Trastuzumab Deruxtecan Extends Survival Over Chemotherapy for Patients With HER2-Positive Metastatic Breast Cancer

third-line treatment of patients with HER2-positive metastatic breast cancer...